Galapagos begins DIVERSITY Phase III study of filgotinib to treat Crohn ’s disease

Belgium-based clinical-stage biotechnology company Galapagos has begun its DIVERSITY Phase III study of filgotinib to treat Crohn ’s disease (CD).
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news